Investors Hangout Stock Message Boards Logo
  • Mailbox
  • Favorites
  • Boards
    • The Hangout
    • NASDAQ
    • NYSE
    • OTC Markets
    • All Boards
  • Whats Hot!
    • Recent Activity
    • Most Viewed Boards
    • Most Viewed Posts
    • Most Posted
    • Most Followed
    • Top Boards
    • Newest Boards
    • Newest Members
  • Blog
    • Recent Blog Posts
    • Recently Updated
    • News
    • Stocks
    • Crypto
    • Investing
    • Business
    • Markets
    • Economy
    • Real Estate
    • Personal Finance
  • Market Movers
  • Interactive Charts
  • Login - Join Now FREE!
  1. Home ›
  2. Stock Message Boards ›
  3. Stock Boards ›
  4. Innovation Pharmaceuticals Inc (IPIX) Message Board

This is why having the before and after endoscopic

Message Board Public Reply | Private Reply | Keep | Replies (2)                   Post New Msg
Edit Msg () | Previous | Next


Post# of 72447
(Total Views: 361)
Posted On: 03/15/2017 2:47:28 PM
Avatar
Posted By: sox0407
This is why having the before and after endoscopic videos of each patient is so important for B-UP.

Celgene paid "$2.6bn ($710m upfront plus $1.9bn in regulatory/development & sales milestones, plus tiered single-digit royalties)" for Mongersen (GED-0301), a potential treatment for Crohn's Disease. Their Phase 2 data were very impressive, but Celgene had to go back to Phase 1 after the deal.

"The recent steps taken by Celgene are also of concern. Given the striking PhII data that they must have seen at the time of the Nogra licensing deal, one would assume a rapid push into pivotal PhIII studies by the company. This has not yet materialised. Indeed the only trial relating to GED-0301 currently registered with either US or EU clinical trial regulators is NCT02367183, a confusingly-designated ‘Phase I‘ study examining endoscopic responses to the highest dose (160mg) of Mongersen in approximately 48 CD patient subjects who will undergo differing therapy regimens. Unlike the PhII study this trial will include (alongside CDAI) an endoscopic confirmation of active disease at enrolment , with primary and secondary outcome measures of reduction in signs of endoscopic disease and CDAI, respectively."

https://lifescicle.wordpress.com/2015/03/26/m...t-bet-yet/

There wont' be any concerns for B-UP. Great trial design by management.


(3)
(0)




Innovation Pharmaceuticals Inc (IPIX) Stock Research Links


  1.  
  2.  


  3.  
  4.  
  5.  


Dont-give-up.jpg




Investors Hangout

Home

Mailbox

Message Boards

Favorites

Whats Hot

Blog

Settings

Privacy Policy

Terms and Conditions

Disclaimer

Contact Us

Whats Hot

Recent Activity

Most Viewed Boards

Most Viewed Posts

Most Posted Boards

Most Followed

Top Boards

Newest Boards

Newest Members

Investors Hangout Message Boards

Welcome To Investors Hangout

Stock Message Boards

American Stock Exchange (AMEX)

NASDAQ Stock Exchange (NASDAQ)

New York Stock Exchange (NYSE)

Penny Stocks - (OTC)

User Boards

The Hangout

Private

Global Markets

Australian Securities Exchange (ASX)

Euronext Amsterdam (AMS)

Euronext Brussels (BRU)

Euronext Lisbon (LIS)

Euronext Paris (PAR)

Foreign Exchange (FOREX)

Hong Kong Stock Exchange (HKEX)

London Stock Exchange (LSE)

Milan Stock Exchange (MLSE)

New Zealand Exchange (NZX)

Singapore Stock Exchange (SGX)

Toronto Stock Exchange (TSX)

Contact Investors Hangout

Email Us

Follow Investors Hangout

Twitter

YouTube

Facebook

Market Data powered by QuoteMedia. Copyright © 2025. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges).
Analyst Ratings & Earnings by Zacks. RT=Real-Time, EOD=End of Day, PD=Previous Day. Terms of Use.

© 2025 Copyright Investors Hangout, LLC All Rights Reserved.

Privacy Policy |Do Not Sell My Information | Terms & Conditions | Disclaimer | Help | Contact Us